KAZIA THERAPEUTICS LTD (KZIA) Form 424B5 — Aug 28, 2026
Kazia Therapeutics filed a prospectus supplement reducing the maximum aggregate offering price of American Depositary Shares that may be sold under its at-the-market facility from $100,000,000 to $80,000,000, including ADSs already sold. The ATM program operates through Leerink Partners under a sales agreement dated March 17, 2026. To date, Kazia has sold 510,000 ADSs for approximately $5,106,516, leaving roughly $74.9 million of capacity still available. Each ADS represents 500 ordinary shares, and the ADSs closed at $16.90 on Nasdaq on August 27, 2026.
Key figures
- Gross Proceeds
- approximately $5,106,516 (aggregate offering price of ADSs sold to date under the Sales Agreement)
- Ads ratio
- 1 ADS represents 500 ordinary shares
- Ads sold to date
- 510000
- Remaining atm capacity
- approximately $74,893,484
- Atm capacity reduced to
- $80,000,000
- Atm capacity reduced from
- $100,000,000
- Ads closing price 2026 08 27
- 16.9
Price after filing
Close on the filing date to close N calendar days later (from $13.58). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.